1. Home
  2. AR vs CORT Comparison

AR vs CORT Comparison

Compare AR & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Antero Resources Corporation

AR

Antero Resources Corporation

N/A

Current Price

$40.05

Market Cap

11.0B

Sector

Energy

ML Signal

N/A

Logo Corcept Therapeutics Incorporated

CORT

Corcept Therapeutics Incorporated

N/A

Current Price

$82.36

Market Cap

9.7B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AR
CORT
Founded
2002
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.0B
9.7B
IPO Year
2013
2001

Fundamental Metrics

Financial Performance
Metric
AR
CORT
Price
$40.05
$82.36
Analyst Decision
Buy
Buy
Analyst Count
22
5
Target Price
$50.59
★ $141.00
AVG Volume (30 Days)
★ 4.3M
881.3K
Earning Date
10-28-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 1027.78
N/A
EPS
★ 3.81
0.09
Revenue
★ $5,275,823,000.00
$761,407,000.00
Revenue This Year
$30.53
$50.42
Revenue Next Year
$2.08
$46.34
P/E Ratio
★ $10.70
$893.00
Revenue Growth
★ 21.97
12.79
52 Week Low
$31.15
$28.66
52 Week High
$45.75
$126.38

Technical Indicators

Market Signals
Indicator
AR
CORT
Relative Strength Index (RSI) 59.58 26.90
Support Level $32.90 $77.38
Resistance Level $45.75 $122.93
Average True Range (ATR) 1.42 5.37
MACD 0.18 -2.82
Stochastic Oscillator 66.74 8.75

Price Performance

Historical Comparison
AR
CORT

About AR Antero Resources Corporation

Antero Resources is an exploration and production firm whose operations represent a pure play in the Marcellus Shale, located in northern West Virginia. The company started in 2002 as an E&P focused on the Barnett Shale (Fort Worth, Texas). Antero redefined itself in Appalachia's Marcellus Shale in 2005. In 2012, shortly before Antero's 2013 IPO, Antero Midstream Partners was formed to handle the company's rapidly growing gas volumes. In 2026, the firm narrowed its focus further by selling its Ohio Utica assets and using the proceeds to acquire additional Marcellus acreage from HG Energy. Just over half of its production and earning power is tied to natural gas, with the remainder mostly NGLs, where it holds a leading position, and some crude oil.

About CORT Corcept Therapeutics Incorporated

Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.

Share on Social Networks: